Braskem Subsidiary Braskem Idesa in Critical Debt Restructuring Talks Amid Severe Financial Distress

summarizeSummary

Braskem's subsidiary, Braskem Idesa, is in critical negotiations to restructure its substantial debt due to severe financial distress, with proposals involving significant capital injections and debt-for-equity swaps, but no agreement has been reached.

check_boxKey Events · Financing and Capital Events · BAK

• Subsidiary Financial Distress

  Braskem Idesa (BI) is experiencing severe financial challenges, including highly constrained liquidity and unsustainable financial leverage, driven by a prolonged petrochemical downcycle and constrained ethane supply.

• Capital Structure Reorganization

  BI is in discussions with bondholders to reorganize its capital structure, with both the company and investors proposing restructuring terms for its 7.450% Senior Secured Notes due 2029 and 6.990% Senior Secured Notes due 2032.

• Braskem Idesa's Proposal

  Includes up to a $300 million shareholder-backed Liquidity Facility and up to a $400 million equity injection from shareholders to repurchase existing notes, offering bondholders options for exchange into new notes or a cash-out at 55% of principal.

• Investor Counterproposal

  Bondholders have presented a counterproposal involving $800 million in new money ($200M New 1L Notes backstopped by AHG, $700M equity from shareholders) and a cash-out option at 55%.

auto_awesomeAnalysis · BAK · Industrial Applications And Services

Braskem S.A.'s subsidiary, Braskem Idesa, is facing severe financial challenges, including highly constrained liquidity and unsustainable debt levels, necessitating a capital structure reorganization. The company has presented a restructuring proposal to bondholders, which includes a significant shareholder-backed liquidity facility of up to $300 million and an equity injection of up to $400 million to repurchase existing notes, along with new take-back notes. Bondholders have made a counterproposal, but no agreement has been reached, indicating ongoing uncertainty. The proposed equity injection represents a substantial portion of Braskem S.A.'s market capitalization, highlighting the critical nature of these negotiations for the parent company's financial health and future. The deep discount cash-out option (55%) in both proposals underscores the severity of the subsidiary's financial distress. Investors should monitor developments closely as the outcome will significantly impact Braskem S.A.'s financial position.